Skip to main content
Log in

Nisoldipine CC and Lisinopril Alone or in Combination for Treatment of Mild to Moderate Systemic Hypertension

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

The efficacy and safety of nisoldipine CC and lisinopril were compared in 278 patients with mild to moderate systemic hypertension in a double-blind, placebo run-in trial. Patients were randomized to nisoldipine CC or lisinopril for 8 weeks to achieve a trough sitting diastolic blood pressure (BP) ≤90 mmHg. Responders were maintained on their optimal dose for a further 8 weeks. Nonresponders were switched to combination therapy and treated for 8 weeks. Twenty-four-hour ambulatory BP monitoring (ABPM) was carried out during placebo and monotherapy. The responder rate of 73.8% with nisoldipine CC after 8 weeks was greater than 56.1% with lisinopril (p = 0.007). The responder rate with combination therapy was 61%. ABPM showed that both nisoldipine CC and lisinopril produced constant blood pressure lowering effects over the 24-hour period and maintained circadian rhythm. Adverse effects were more frequent with nisoldipine CC (headache and peripheral edema) than with lisinopril (cough) monotherapy. Nisoldipine CC monotherapy was at least as effective as lisinopril monotherapy in the management of mild to moderate hypertension. Both agents were well tolerated. Combination therapy with nisoldipine CC and lisinopril was effective and well tolerated in patients with blood pressure not controlled by monotherapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Massie BM, Hirsch AT, Inouye IK, Tubau JF. Calcium channel blockers as antihypertensive agents. Am J Med 1984;77(Suppl 4A):135–121.

    PubMed  CAS  Google Scholar 

  2. Spivak C, Ocken S. Frishman WH. Calcium antagonists: Clinical use in the treatment of systemic hypertension. Drugs 1983;25:154–177.

    Article  Google Scholar 

  3. Halperin AK, Cubeddu LX. The role of calcium channel blockers in the treatment of hypertension. Am Heart J 1986;111;363–382.

    Article  PubMed  CAS  Google Scholar 

  4. Opie LH. Calcium channel antagonists: Part VII: Are second generation agents better? In Opie LH (ed). Drugs for the Heart. Philadelphia: WB Saunders, 1995:280–285.

    Google Scholar 

  5. Neumayer HH, Gellert J, Luft FE. Calcium antagonists and renal protection. Ren Fail 1993;153:353–358.

    Google Scholar 

  6. Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988;8:285–290.

    Article  PubMed  CAS  Google Scholar 

  7. Ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 1994;154:1185–1202.

    Article  PubMed  CAS  Google Scholar 

  8. Brandt D. Calcium antagonists in the therapy of ventricular hypertrophy. Wien Med Wochenschr 1993;143:510–513.

    PubMed  CAS  Google Scholar 

  9. Rosenthal T, Frohlich ED. Nisoldipine in the treatment of hypertension. Adv Ther 1993;10:151–156.

    Google Scholar 

  10. Man-in-t-Veld AJ. Calcium antagonists in hypertension. Am J Med 1989;86:6–14.

    Article  CAS  Google Scholar 

  11. Nakaya H, Hattori Y, Nakao Y, Kanno M. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists. Eur J Pharmacol 1988;143:35–43.

    Article  Google Scholar 

  12. Friedel HA, Sorkin EM. Nisoldipine: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficiency in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988;36≐2–731.

    Google Scholar 

  13. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995;75:41E–45E.

    Article  PubMed  CAS  Google Scholar 

  14. Lewis BS. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. Am J Cardiol 1995;75:46E–53E.

    Article  PubMed  CAS  Google Scholar 

  15. Lang H, Christensen J. Long-term treatment of essential hypertension with lisinopril or a low-dose lisinopril/hydrochlorothiazide combination. Drug Dev Res 1995;(Suppl. 2):30–33.

    Google Scholar 

  16. Kiowski W, Osswald S. Circadian variation of ischemic cardiac events. J Cardiovasc Pharmacol 1993;21(Suppl. 2):S45–S48.

    PubMed  Google Scholar 

  17. Graney WF. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension. Am J Med 1992:93(Suppl. 2A)∋S–65S.

    Google Scholar 

  18. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six anti-hypertensive agents with placebo. N Engl J Med 1993:328:914–21.

    Article  PubMed  CAS  Google Scholar 

  19. Weir MR, Josselson J, Giard MJ, et al. Sustained-release diltizem compared with atenolol monotherapy for mild to moderate systemic hypertension. Am J Cardiol 1987;60:361–411.

    Article  Google Scholar 

  20. Murdoch D, Brogden RN. Sustained-release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991;41:737–779.

    PubMed  CAS  Google Scholar 

  21. Carruthers SG, Vint-Reed C. Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Clin Invest Med 1993;16:386–394.

    PubMed  CAS  Google Scholar 

  22. Ruddy TD, Wright JM, Savard D, et al. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. Cardiovasc Drugs Ther 1995;9:413–420.

    Article  PubMed  CAS  Google Scholar 

  23. Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478–505.

    PubMed  CAS  Google Scholar 

  24. Thurston H, Mimran A, Zanchetti A, et al. A double-blind comparison of perindopril and atenolol in essential hypertension. J Hum Hyperten 1990;4:547–552.

    CAS  Google Scholar 

  25. Friedel HA, Sorkin EM. Nisoldipine—a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficiency in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drug 1988;36:682–731.

    CAS  Google Scholar 

  26. Zanchetti A, Bianchi L, Bozza M, et al. Antihypertensive effects of nifedipine GITS on clinic and ambulatory blood pressure in essential hypertensives. High Blood Pressure 1994;3=-46.

  27. Guntzel P, Kobrin I, Pasquier C, et al. The effect of cilazapril, a new antiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. J Cardiovasc Pharmacol 1991;17:8–12.

    Article  PubMed  CAS  Google Scholar 

  28. Myers MG. Use of trough: Peak ratio in the assessment of antihypertensive drug therapy. Can J Cardiol 1994;10(Suppl. D):17D–20D.

    PubMed  Google Scholar 

  29. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharmacol Ther 1988;44:540–545.

    Article  PubMed  CAS  Google Scholar 

  30. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken when prescribed? A novel assessment technique. JAMA 1989;261:3272–3277.

    Article  Google Scholar 

  31. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patients medication compliance. Arch Intern Med 1990;150:1881–1884.

    Article  PubMed  CAS  Google Scholar 

  32. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154–83.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruddy, T.D., Fodor, J.G. Nisoldipine CC and Lisinopril Alone or in Combination for Treatment of Mild to Moderate Systemic Hypertension. Cardiovasc Drugs Ther 11, 581–590 (1997). https://doi.org/10.1023/A:1007744005480

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007744005480

Navigation